Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Impax Laboratories has received the US Food and Drug Administration (FDA) approval for its abbreviated new drug application for generic version of Cymbalta delayed-release (duloxetine hydrochloride) 20, 30 and 60mg capsules.
Subscribe to our email newsletter
Cymbalta is marketed by Eli Lilly and Company.
Cymbalta is a serotonin and norepinephrine reuptake inhibitor indicated for the treatment of major depressive disorder, generalised anxiety disorder, diabetic peripheral neuropathic pain, and fibromyalgia.
Impax Laboratories is a technology-based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products.